Phase I PIANO trial—PIPAC-oxaliplatin and systemic nivolumab combination for gastric cancer peritoneal metastases: clinical and translational outcomes
The first-in-human trial combining PIPAC-OX and nivolumab demonstrated safety and tolerability, coupled with enhanced T-cell infiltration within peritoneal tumors. This trial sets the stage for future combinations of systemic immunotherapy with locoregional intraperitoneal treatments.
Authors
- Patrick Tan (ORCID: https://orcid.org/0000-0002-0179-8048)
- Anne Hoorens (ORCID: https://orcid.org/0000-0002-0736-2034)
- Wei Peng Yong (ORCID: https://orcid.org/0000-0003-4404-3777)
- Takeshi Hagihara (ORCID: https://orcid.org/0009-0007-9263-1553)
- Wouter Willaert (ORCID: https://orcid.org/0000-0002-0885-6749)
- Seng Wee Cheo (ORCID: https://orcid.org/0000-0003-2879-5346)
- Matthew Chau Hsien Ng (ORCID: https://orcid.org/0000-0003-3170-4126)
- Kie Kyon Huang (ORCID: https://orcid.org/0000-0003-4104-8951)
- Asim Shabbir (ORCID: https://orcid.org/0000-0002-2490-6478)
- Robert Walsh (ORCID: https://orcid.org/0000-0003-0985-606X)
- Sathiyamoorthy Selvarajan (ORCID: https://orcid.org/0000-0002-2949-7474)
- Jolene Si Min Wong (ORCID: https://orcid.org/0000-0002-9750-5755)
- Wim Ceelen (ORCID: https://orcid.org/0000-0001-7692-4419)
- Gyuri Kim (ORCID: https://orcid.org/0000-0002-2242-2816)
- Huey Yew Jeffrey Lum (ORCID: https://orcid.org/0000-0002-3513-2404)
- Raghav Sundar (ORCID: https://orcid.org/0000-0001-9423-1368)
- Chin Jin Seo
- Angel Pang (ORCID: https://orcid.org/0000-0003-1001-5102)
- Wee Han Ang (ORCID: https://orcid.org/0000-0003-2027-356X)
- Karel Geboes
- Wei Qiang Leow (ORCID: https://orcid.org/0000-0001-6003-9837)
- Eduard Callebout (ORCID: https://orcid.org/0000-0003-1899-3410)
- Jimmy Bok Yan So (ORCID: https://orcid.org/0000-0002-9772-7905)
- Hon Lyn Tan (ORCID: https://orcid.org/0000-0001-5966-2293)
- Daryl Kai Ann Chia (ORCID: https://orcid.org/0000-0001-9936-1225)
- Ainsley Ryan Yan Bin Lee (ORCID: https://orcid.org/0000-0002-5896-2929)
- Claramae S. Chia
- Hui Pang (ORCID: https://orcid.org/0000-0002-2806-2276)
- Hu Ma (ORCID: https://orcid.org/0000-0003-1654-1576)
- Jing Zhao (ORCID: https://orcid.org/0000-0003-3315-9256)
- Gary Chan (ORCID: https://orcid.org/0000-0002-1338-132X)
- Angie Tan
- C-A J Ong
- C C C Soh
Institutions
- National University of Singapore (SG)
- Singapore General Hospital (SG)
- Ghent University Hospital (BE)
- National University Cancer Institute, Singapore (SG)
- Duke-NUS Medical School (SG)
- National Cancer Centre Singapore (SG)
- National University Hospital (SG)
- National University Health System (SG)
Publication Details
- Journal
- ESMO Open
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1016/j.esmoop.2024.103681
- Citations
- 13
- Primary Topic
- Intraperitoneal and Appendiceal Malignancies
- Type
- article
- Field-Weighted Citation Impact
- 7.45
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- BeiGene
- Natera
- National Research Foundation
- National University of Singapore
- National Research Foundation Singapore
- Fonds Wetenschappelijk Onderzoek
- Eisai
- Astellas Pharma
- National University Cancer Institute, Singapore
- Servier
- National University Health System
- Vlaamse regering
- Ipsen
- Medical Research Council
- National Medical Research Council
- Daiichi Sankyo Europe